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As emerging in the recent literature, CD1a has been regarded as a molecule whose expression may reflect tumour evolution. The
aim of the present work was to investigate the expression of CD1a in a series of Barrett’s metaplasia (BM), gastric type (GTBM), with
and without follow-up, in order to analyse whether its expression may help to diagnose this disease and to address the outcome.
Indeed, GTBM may be confused sometimes with islets of ectopic gastric mucosa and its evolution towards dysplasia (Dy) or
carcinoma (Ca) could not be foreseen. We showed a significant higher expression of CD1a in GTBM than in both Dy and Ca;
nevertheless, the number of positive GTBM was significantly lower in the group of cases that at follow-up underwent Dy or Ca. Our
data address that CD1a may be a novel biomarker for BM and that its expression may help to predict the prognosis of this pathology.
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CD1a is a surface glycoprotein of 43–49kDa that has been shown
to be expressed by dendritic cells (DCs), cortical thymocytes and
Langerhans cells of the skin (Dezutter-Dambuyant et al, 1990;
Krenacs et al, 1993; Gregory et al, 2000). Moreover, the research of
CD1a is commonly used to differentiate various cutaneous T-cell
lymphomas from B-cell lymphomasand pseudolymphomas (Arai
et al, 1999; Schmuth et al, 2001).
The antitumoral role of CD1a was recently proposed (Coventry
and Morton, 2003a; Coventry and Heinzel, 2004; La Rocca et al,
2004). We also recently described that CD1a could be expressed
in metaplastic epithelium of Barrett’s oesophagus, both gastric
and intestinal types, while normal gastric and colonic mucosa
were negative to this marker (Cappello et al, 2003). In particular,
we postulated that this marker may be useful in diagnosing
Barrett’s metaplasia (BM) and we hypothesised that its expression
could predict a favourable outcome of this disease (Cappello,
2004).
Indeed, BM may evolve towards dysplasia (Dy) or carcinoma
(Ca) (Cameron and Carpenter, 1997; Malhi-Chowla et al, 2000;
Moreto, 2003). Nevertheless, to date, we do not have any marker
that could help to predict BM evolution.
The aim of the present work was to detect CD1a expression
in a large series of BM, Dy and Ca at the time of diagnosis
and at follow-up. We would verify the diagnostic role of CD1a
for BM and confirm our hypothesis concerning its prognostic
role.
MATERIALS AND METHODS
Sample collection
We selected retrospectively from our files, 222 cases as follows: 166
specimens were BM of gastric type (GTBM) that underwent follow
up; moreover, we selected 37 specimens of Dy and 19 of Ca that did
not undergo follow-up. Finally, as control group, we selected 10
specimens from normal gastric mucosa. Sample collection was
performed according to ethical standards. In addition, we
collected, from the 166 cases of GTBM, the specimens that
underwent follow-up, commonly between 12 and 36 months from
first diagnosis; in 134 cases, the diagnosis of BM was confirmed
(FU-GTBM), while in 23 cases, GTBM evolved towards dysplasia
(FU-Dy) and in nine cases towards carcinoma (FU-Ca).
Immunohistochemistry
We subjected all specimens of both groups to immunohistochem-
istry for CD1a, using a monoclonal antibody (DAKO, clone O10,
1:50) revealed by an avidin–biotin system (DAKO – LSAB2). In
detail, 5mm sections were subjected to immunohistochemistry in
triplicate, in order to minimize false-positivity errors. Nonimmune
sera were substituted for negative controls and appropriate
positive controls were run concurrently. 3-30-Diaminobenzidine
(DAB chromogen solution, DAKO, cat. no. K3467) was used as
develop chromogen. A nuclear counterstaining with haematoxylin
(DAKO, cat. no. S2020) was finally performed. The immunostain-
ings were valued from two independent observers (FC and FR).
Statistical analysis
For all groups of patients, data regarding positivity to CD1a
expression were plotted using MS Excel software. Statistical
analysis was performed using the Mann–Whitney U-test in order
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sto verify the presence of a significant difference between CD1a-
positive and -negative cases of GTBM that had undergone follow-
up. In all cases, data were considered significant for values of
Po0.05.
RESULTS
Immunohistochemistry
Thin sections of oesophageal specimens from all subjects were
subjected to immunohistochemical analyses in order to evaluate
CD1a expression in both metaplastic and dysplastic/cancerous
tissues.
As summarised in Figure 1, the frequency of expression of CD1a
was a distinguishing feature between metaplastic and dysplastic/
carcinomatous lesions. In particular, the group of GTBM presented
a higher number of CD1a-positive cases (166 out of 222, 81%),
while this marker was found rather infrequently in both Dy (37 out
of 222, 13.5%) and Ca (19 out of 222, 5.3%) groups.
The aim of the present study was also to evaluate the usefulness
of CD1a expression as a marker of evolution of the metaplastic
lesions, as metaplasia has been regarded as a predisposing
condition for the development of oesophageal Ca (Malhi-Chowla
et al, 2000; Moreto, 2003). To this end, as shown in Figure 2, most
of FU-Dy and FU-Ca cases evolved from the group of subjects that
at the time of the first diagnosis featured the absence of CD1a
protein. Statistical analysis showed a significant difference between
FU-GTBM (Po0.001), FU-Dy (Po0.0002) and FU-Ca (Po0.0005)
comparing CD1aþ and CD1a  groups.
Finally, Figure 3 shows immunohistochemical results. Positivity
for CD1a in BM specimens was present not only at the level of
intraepithelial DCs (Figure 3A and B), but above all in metaplastic
epithelium (Figure 3A and C), while only few scattered stromal
elements were found between metaplastic glands (Figure 3C).
Moreover, normal gastric mucosa (Figure 3F) was always negative
for CD1a, as well as most of the cases of Dy (Figure 3D) and Ca
(Figure 3E).
DISCUSSION
CD1a is usually expressed by immature DCs (Arrighi et al, 2003).
Its expression by APC was recently supposed to be correlated to a
better prognosis in breast cancers (Coventry and Morton, 2003b;
Poindexter et al, 2004; Thomachot et al, 2004). In particular, its
overexpression by axillary lymph nodes could prevent lymph node
metastases (Poindexter et al, 2004); nevertheless, the authors of
this work found a higher number of mature CD83-positive DCs,
but not of immature CD1a-positive DCs, in tumour-free sentinel
lymph nodes than those containing tumours. In addition, its
expression by epithelial cells of in situ ductal Ca of the breast was
also suggested (Coventry and Heinzel, 2004). Indeed, the density of
CD1a
þ DCs within human tumours has been already associated
with longer survival.
Barrett’s oesophagous is an acquired metaplastic condition that
results by a phenotypic switch of undifferentiated epithelial
elements present in oesophageal mucosa (Fahmy and King, 1993;
Chandrasoma et al, 2001). Barrett’s metaplasia of gastric type is
characterised by the presence of columnar cells resembling the
gastric foveolar ones (Zwas et al, 1986). Although the presence of a
severe inflammation was recently associated to a higher possibility
to progress to cancer (Fitzgerald et al, 2002), the lamina propria
surrounding metaplastic epithelium shows commonly a mild
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Figure 1 Distribution of specimens with respect to CD1a positivity at
the time of diagnosis.
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Figure 2 Diagrams of follow-up analysis for the group of patients
(n¼166) diagnosed for BM (BMGT). As shown, 80.7% of lesions (n¼134)
were confirmed as BMGT, 13.9% (n¼23) developed Dy, while 5.4%
(n¼9) developed Ca. Lesions of the group originally classified as CD1a 
were significantly more prone to evolve to Dy (Po0.0002) or Ca
(Po0.0005) with respect to the CD1aþ group.
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Figure 3 Panel of immunohistochemistry microphotographs showing a
biopsy for BM (A) with positive CD1a dendritic elements between
epithelial cells (B), as well as positive epithelial cells at the level of
metaplastic glands (C). By contrast, CD1a was absent in dysplastic (D) and
neoplastic (E) glands as well as in normal gastric mucosa (F).
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sinflammatory infiltrate (Lee, 1999). Indeed, until now, the Dy
arising on BM is the only well-established preneoplastic lesion of
the oesophageal adenocarcinoma (Menke-Pluymers et al, 1993;
Clark et al, 1996).
We already showed, in a smaller series, that CD1a may be
expressed by epithelial cells of BM, both gastric and intestinal
types (Cappello et al, 2003). In particular, we postulated a
diagnostic role of this marker and supposed that it may also be
useful to predict prognosis. Moreover, we already hypothesised a
proimmunitary role of CD1a expression by epithelial cells (La
Rocca et al, 2004), in accordance to Coventry and Heinzel (2004).
In the present work, we demonstrated that CD1a may have a
diagnostic role for BM. In particular, the expression of CD1a by
metaplastic epithelial cells might help to distinguish GTBM from
the presence of ectopic gastric epithelium in the oesophageal
mucosa, since gastric epithelium resulted negative. Moreover, our
data strongly suggest a prognostic role of the expression of CD1a
on GTBM; indeed, the number of FU-Dy and FU-Ca cases was
significantly higher in the CD1a  GTBM group than in the
CD1aþ GTBM group.
In our opinion, the present results may confirm that increased
CD1a expression not only in DCs but above all in epithelial cells
may prevent tumour progression, for instance regarding the
evolution of GTBM towards Ca. The expression of CD1a on
metaplastic epithelial cells might be induced by local humoral
factors, like inflammatory cytokines, as well as other unknown
stimulatory molecules.
In conclusion, our hypotheses concerning the diagnostic and
prognostic role of CD1a for BM may be confirmed by the present
work. Moreover, we suppose that CD1a expression may have an
antitumoral role in BM mucosa, and also, as postulated, in
neoplastic diseases arising at other anatomic sites (Coventry and
Morton, 2003a; Coventry and Heinzel, 2004; Poindexter et al,
2004). As a future objective, epithelial CD1aþ cells interaction
with DCs or T cells remains to be further investigated. At this
stage, the possible explanation for the role of CD1a ectopic
expression by epithelial elements remains unclear.
Regarding the intercellular signalling strategies, we suppose that
DCs induce tumour cells apoptosis following the production of
certain extracellular cytokines, as already postulated (Joo et al,
2002). It may be assumed that this is only one of the processes that
take place following DCs activation. Considering the importance of
intercellular signalling, mediated by both soluble factors and
extracellular matrix-bound molecules, a future goal could be to
determine the cytokine expression pattern of Barrett’s metaplastic
cells, and by what means it could modulate antitumour immune
response. Indeed, although BM commonly shows a mild inflam-
matory infiltrate, we will consider now with great interest the
investigation of the cellular features and molecular pattern of these
immunitary cells.
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